CN1125725A - 一类海克林碱衍生物及它的用途 - Google Patents

一类海克林碱衍生物及它的用途 Download PDF

Info

Publication number
CN1125725A
CN1125725A CN94114057A CN94114057A CN1125725A CN 1125725 A CN1125725 A CN 1125725A CN 94114057 A CN94114057 A CN 94114057A CN 94114057 A CN94114057 A CN 94114057A CN 1125725 A CN1125725 A CN 1125725A
Authority
CN
China
Prior art keywords
derivative
selagine
physiological saline
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN94114057A
Other languages
English (en)
Chinese (zh)
Inventor
朱大元
唐烯灿
林金来
朱诚
沈竞康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Priority to CN94114057A priority Critical patent/CN1125725A/zh
Priority to DE69530706T priority patent/DE69530706T2/de
Priority to EP95941572A priority patent/EP0806416B1/en
Priority to US08/860,524 priority patent/US5929084A/en
Priority to AU42966/96A priority patent/AU4296696A/en
Priority to US09/799,127 priority patent/USRE38460E1/en
Priority to DK95941572T priority patent/DK0806416T3/da
Priority to AT95941572T priority patent/ATE239708T1/de
Priority to ES95941572T priority patent/ES2199259T3/es
Priority to JP52010296A priority patent/JP3545416B2/ja
Priority to PCT/CN1995/000100 priority patent/WO1996020176A1/zh
Priority to PT95941572T priority patent/PT806416E/pt
Publication of CN1125725A publication Critical patent/CN1125725A/zh
Priority to JP2003148129A priority patent/JP4105592B2/ja
Priority to JP2007174592A priority patent/JP2007246545A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN94114057A 1994-12-28 1994-12-28 一类海克林碱衍生物及它的用途 Pending CN1125725A (zh)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CN94114057A CN1125725A (zh) 1994-12-28 1994-12-28 一类海克林碱衍生物及它的用途
AT95941572T ATE239708T1 (de) 1994-12-28 1995-12-26 Huperzin-derivate, ihre herstellung und ihre verwendung
ES95941572T ES2199259T3 (es) 1994-12-28 1995-12-26 Derivados de huperzina, su preparacion y su utilizacion.
US08/860,524 US5929084A (en) 1994-12-28 1995-12-26 Huperzine A derivatives, their preparation and their use
AU42966/96A AU4296696A (en) 1994-12-28 1995-12-26 Huperzine a derivatives, their preparation and their use
US09/799,127 USRE38460E1 (en) 1994-12-28 1995-12-26 Huperzine A derivatives, their preparation and their use
DK95941572T DK0806416T3 (da) 1994-12-28 1995-12-26 Huperzinderivater, deres fremstilling og anvendelse
DE69530706T DE69530706T2 (de) 1994-12-28 1995-12-26 Huperzin-derivate, ihre herstellung und ihre verwendung
EP95941572A EP0806416B1 (en) 1994-12-28 1995-12-26 Huperzine a derivatives, their preparation and their use
JP52010296A JP3545416B2 (ja) 1994-12-28 1995-12-26 フペルジンａ誘導体、その製造およびその使用
PCT/CN1995/000100 WO1996020176A1 (en) 1994-12-28 1995-12-26 Huperzine a derivatives, their preparation and their use
PT95941572T PT806416E (pt) 1994-12-28 1995-12-26 Derivados de huperzina a sua preparacao e utilizacao
JP2003148129A JP4105592B2 (ja) 1994-12-28 2003-05-26 フペルジンａ誘導体、その製造およびその使用
JP2007174592A JP2007246545A (ja) 1994-12-28 2007-07-02 フペルジンａ誘導体、その製造およびその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN94114057A CN1125725A (zh) 1994-12-28 1994-12-28 一类海克林碱衍生物及它的用途

Publications (1)

Publication Number Publication Date
CN1125725A true CN1125725A (zh) 1996-07-03

Family

ID=5037011

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94114057A Pending CN1125725A (zh) 1994-12-28 1994-12-28 一类海克林碱衍生物及它的用途

Country Status (11)

Country Link
US (1) US5929084A (enExample)
EP (1) EP0806416B1 (enExample)
JP (3) JP3545416B2 (enExample)
CN (1) CN1125725A (enExample)
AT (1) ATE239708T1 (enExample)
AU (1) AU4296696A (enExample)
DE (1) DE69530706T2 (enExample)
DK (1) DK0806416T3 (enExample)
ES (1) ES2199259T3 (enExample)
PT (1) PT806416E (enExample)
WO (1) WO1996020176A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1308312C (zh) * 2003-11-13 2007-04-04 中国科学院上海药物研究所 石杉碱乙双分子和双功能团衍生物、制备方法及它的用途
CN100398093C (zh) * 2003-03-14 2008-07-02 德比欧药物研究有限公司 皮下给药系统、其制备方法及其治疗胆碱能缺乏障碍的用途
CN100528844C (zh) * 2007-04-20 2009-08-19 中国科学院昆明植物研究所 石杉碱甲衍生物,其制备方法和其应用
CN101797223B (zh) * 2009-02-06 2012-05-23 上海交通大学医学院 石杉碱甲眼用制剂及其应用
CN116925039A (zh) * 2023-07-18 2023-10-24 陕西中药研究所(陕西医药信息中心) 一种n-(3,5,6-三甲基吡嗪-2-亚甲基)-石杉碱甲及其合成方法和应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
NL1009437C2 (nl) * 1998-06-18 1999-12-21 Xenobiosis Extractiewerkwijze.
EP1604653A1 (en) 1998-09-30 2005-12-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
US6159986A (en) * 1999-11-02 2000-12-12 Altman; David A. Compounds and therapy for resisting memory loss in humans
US6436972B1 (en) 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
WO2001085985A1 (en) * 2000-05-05 2001-11-15 United States Army Medical Research And Material Command Assay for detecting, measuring and monitoring the activities and concentrations of proteins and methods of use thereof
US6369052B1 (en) 2000-08-07 2002-04-09 Georgetown University Combination of huperzine and nicotinic compounds as a neuroprotective agent
KR100390777B1 (ko) * 2000-12-19 2003-07-10 한국화학연구원 피리돈 유도체의 제조방법
DE10144041B9 (de) * 2001-09-07 2012-07-26 Leica Mikrosysteme Gmbh Gerät zum selbsttätigen Zuführen von Objektträgern zu einem Eindeckautomaten
NZ542459A (en) * 2003-03-14 2008-12-24 Debio Rech Pharma Sa Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
WO2006050359A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
US20060264455A1 (en) * 2005-05-23 2006-11-23 Schachter Steven C Use of huperzine for disorders
WO2007056580A2 (en) * 2005-11-08 2007-05-18 Pharmadyn, Inc. Methods and compositions for treating diseases associated with pathogenic proteins
WO2007127474A2 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
US8097726B2 (en) * 2006-05-17 2012-01-17 Industrial Technology Research Institute Huperzine a compound for treatment of alzheimer's disease
EP2044937A4 (en) * 2006-07-05 2010-10-27 Tianjin Hemay Bio Tech Co Ltd ANALGESIC DERIVATIVES 5,9 - METHANOCYCLO OCTA (B) PYRIDINE - 2 (1H) - ONE, PROCESS FOR PREPARING SAME AND USE THEREOF
TWI404531B (zh) * 2007-05-17 2013-08-11 Ind Tech Res Inst 石杉鹼甲化合物及包含此化合物之醫藥組合物
US20110224245A1 (en) * 2008-09-04 2011-09-15 President And Fellows Of Harvard College Treatment Of Neurological Disorders Using Huperzine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177082A (en) * 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US4929731A (en) * 1989-02-21 1990-05-29 University Of Pittsburgh Method for the synthesis of huperzine A and analogs thereof and compounds useful therein
US5104880A (en) * 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
US5684018A (en) * 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100398093C (zh) * 2003-03-14 2008-07-02 德比欧药物研究有限公司 皮下给药系统、其制备方法及其治疗胆碱能缺乏障碍的用途
CN1308312C (zh) * 2003-11-13 2007-04-04 中国科学院上海药物研究所 石杉碱乙双分子和双功能团衍生物、制备方法及它的用途
CN100528844C (zh) * 2007-04-20 2009-08-19 中国科学院昆明植物研究所 石杉碱甲衍生物,其制备方法和其应用
CN101797223B (zh) * 2009-02-06 2012-05-23 上海交通大学医学院 石杉碱甲眼用制剂及其应用
CN116925039A (zh) * 2023-07-18 2023-10-24 陕西中药研究所(陕西医药信息中心) 一种n-(3,5,6-三甲基吡嗪-2-亚甲基)-石杉碱甲及其合成方法和应用

Also Published As

Publication number Publication date
JP2003306481A (ja) 2003-10-28
JP2007246545A (ja) 2007-09-27
US5929084A (en) 1999-07-27
WO1996020176A1 (en) 1996-07-04
DE69530706D1 (de) 2003-06-12
AU4296696A (en) 1996-07-19
JP3545416B2 (ja) 2004-07-21
EP0806416A1 (en) 1997-11-12
JPH10511651A (ja) 1998-11-10
EP0806416B1 (en) 2003-05-07
ATE239708T1 (de) 2003-05-15
ES2199259T3 (es) 2004-02-16
PT806416E (pt) 2003-09-30
DK0806416T3 (da) 2003-09-01
JP4105592B2 (ja) 2008-06-25
DE69530706T2 (de) 2004-03-25
EP0806416A4 (en) 1998-04-15

Similar Documents

Publication Publication Date Title
EP2488531B1 (en) Synthetic methods for spiro-oxindole compounds
KR101922266B1 (ko) 선택적 글리코시다제 억제제 및 그의 용도
WO1996020176A1 (en) Huperzine a derivatives, their preparation and their use
EP1078928B1 (fr) Dérivés de la pyridine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CN111712491B (zh) 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN115636830B (zh) 一种苦参碱衍生物及其合成方法和用途
EP2486013B1 (en) Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
KR100704009B1 (ko) 염증억제 활성을 가지는6-알킬아미노-2-메틸-2'-(ｎ-메틸치환술폰아미도)메틸-2ｈ-1-벤조피란 유도체
CN106883225B (zh) 一种具有1,2,4-恶二唑-结构片段的香豆素衍生物及其应用
CN105906598A (zh) 白杨素衍生物及其制备方法和应用
EP1914232B1 (en) N-dihydroxyalkyl-substituted 2-oxoimidazole derivatives
McQuaid et al. Substituted 5-amino-4, 5, 6, 7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity
CN108997121A (zh) 厚朴酚衍生物在制备治疗中枢神经系统疾病药物中的应用
AU781663B2 (en) New pyrimidin-4-one compounds, a process for their preparation and pharmaceutical compositions containing them
CN114230582A (zh) 新型一叶萩碱二聚体及其制备方法和应用
EP1670766A1 (de) Bicyclische iminos urederivate als inhibitoren von matrix-metalloproteinasen
CN118724808B (zh) 四氢异喹啉类衍生物抗菌剂及其制备方法、包含其的组合物、药物制剂及三者的应用
RU2792034C2 (ru) Тетрагидроизохинолиновое соединение, способ его получения, фармацевтическая композиция, содержащая такое соединение, и его применение
SU1480771A3 (ru) Способ получени 9-амино-5,6,6 @ ,7-тетрагидро-4Н-бензо @ , @ тиазоло @ 4,5- @ хинолинов или их кислотно-аддитивных солей в виде рацемата, энантиомеров или смеси энантиомеров
CN103242214A (zh) 一种吲哚衍生物及其制备方法
WO2020008317A1 (en) Acylsufonamide compounds useful as ep3 receptor antagonists
KR100746939B1 (ko) 염증억제 활성을 가지는ｎ-[1'-치환술폰아미드-스파이로(2ｈ-1-벤조피란-2,4-피페리딘)-6-일]치환아민 유도체, 그의 약학적으로허용가능한 염, 그의 제조방법 및 그의 용도
Patil et al. Total Synthesis of 12, 13‐Dibenzyl‐banistenoside B and Analogs
AU762990B2 (en) New benzo(3,4)cyclobuta(1,2-C)pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
CN102666486A (zh) 氮杂双环辛烷类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication